Andrew Tsai
Stock Analyst at Jefferies
Total Price Targets
20
Stocks Covered
16
Sectors
Communication Services, Healthcare, Utilities
Most Recent
Mar 16, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Andrew Tsai
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| ANRO | Alto Neuroscience, Inc. | $35.00 | $24.73 | +41.5% | 1 | Mar 16, 2026 |
| XENE | Xenon Pharmaceuticals Inc. | $65.00 | $56.81 | +14.4% | 2 | Mar 9, 2026 |
| ATAI | Atai Beckley N.V | $10.00 | $4.12 | +142.7% | 2 | Mar 6, 2026 |
| MRNA | Moderna, Inc. | $37.00 | $44.65 | -17.1% | 1 | Mar 3, 2026 |
| SRPT | Sarepta Therapeutics, Inc. | $30.00 | $21.60 | +38.9% | 2 | Mar 3, 2026 |
| DNLI | Denali Therapeutics Inc. | $40.00 | $18.49 | +116.3% | 1 | Mar 2, 2026 |
| BBIO | BridgeBio Pharma, Inc. | $100.00 | $69.25 | +44.4% | 1 | Feb 12, 2026 |
| HELP | Cybin Inc. Common Stock | $22.00 | $5.20 | +323.1% | 1 | Feb 1, 2026 |
| VTGN | VistaGen Therapeutics, Inc. | $0.90 | $0.63 | +42.9% | 2 | Dec 17, 2025 |
| PRAX | Praxis Precision Medicines, Inc. | $300.00 | $330.59 | -9.3% | 1 | Oct 16, 2025 |
| BIIB | Biogen Inc. | $190.00 | $186.69 | +1.8% | 1 | Sep 25, 2025 |
| MCS | The Marcus Corporation | $30.00 | $17.49 | +71.5% | 1 | Jul 18, 2025 |
| RCKT | Rocket Pharmaceuticals, Inc. | $2.50 | $3.56 | -29.9% | 1 | May 28, 2025 |
| GEV | GE Vernova Inc. | $165.00 | $1069.31 | -84.6% | 1 | Oct 21, 2024 |
| RAPP | Rapport Therapeutics, Inc. Common Stock | $35.00 | $34.13 | +2.6% | 1 | Jul 2, 2024 |
| RLMD | Relmada Therapeutics, Inc. | $8.00 | $7.66 | +4.5% | 1 | Oct 13, 2022 |
Recent Activity
- Mar 16, 2026— Set$35.00price target onANRO(Alto Neuroscience, Inc.)
- Mar 9, 2026— Set$100.00price target onXENE(Xenon Pharmaceuticals Inc.)
- Mar 9, 2026— Set$65.00price target onXENE(Xenon Pharmaceuticals Inc.)
- Mar 6, 2026— Set$10.00price target onATAI(Atai Beckley N.V)
- Mar 3, 2026— Set$37.00price target onMRNA(Moderna, Inc.)
- Mar 3, 2026— Set$30.00price target onSRPT(Sarepta Therapeutics, Inc.)
- Mar 2, 2026— Set$40.00price target onDNLI(Denali Therapeutics Inc.)
- Feb 12, 2026— Set$100.00price target onBBIO(BridgeBio Pharma, Inc.)
- Feb 1, 2026— Set$22.00price target onHELP(Cybin Inc. Common Stock)
- Dec 17, 2025— Set$0.90price target onVTGN(VistaGen Therapeutics, Inc.)
- Oct 16, 2025— Set$300.00price target onPRAX(Praxis Precision Medicines, Inc.)
- Sep 25, 2025— Set$190.00price target onBIIB(Biogen Inc.)
- Jul 18, 2025— Set$30.00price target onMCS(The Marcus Corporation)
- May 28, 2025— Set$2.50price target onRCKT(Rocket Pharmaceuticals, Inc.)
- May 20, 2025— Set$5.00price target onATAI(Atai Beckley N.V)
- Oct 21, 2024— Set$165.00price target onSRPT(Sarepta Therapeutics, Inc.)
- Oct 21, 2024— Set$165.00price target onGEV(GE Vernova Inc.)
- Jul 2, 2024— Set$35.00price target onRAPP(Rapport Therapeutics, Inc. Common Stock)
- Oct 13, 2022— Set$8.00price target onRLMD(Relmada Therapeutics, Inc.)
- Jul 22, 2022— Set$6.00price target onVTGN(VistaGen Therapeutics, Inc.)
Frequently Asked Questions
Who is Andrew Tsai?
Andrew Tsai is a stock analyst at Jefferies covering 16 stocks primarily in Communication Services, Healthcare, Utilities. They have issued 20 price targets since Jul 22, 2022.
What stocks does Andrew Tsai cover?
Andrew Tsai currently covers 16 stocks, including XENE, ATAI, SRPT, VTGN, ANRO.
What is Andrew Tsai's latest price target?
Andrew Tsai's most recent price target was $35.00 on ANRO (Alto Neuroscience, Inc.), set on Mar 16, 2026.
What is Andrew Tsai's highest price target?
Andrew Tsai's highest issued price target is $300.00 on PRAX, set on Oct 16, 2025.
More Analysts at Jefferies
Coverage based on publicly published price targets. Not investment advice.